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Purpose: The human kallikrein-2 (hK2) protein and two single nucleotide polymorphism (SNPs) (rs2664155,
rs198977) of the gene are associated with prostate cancer risk. We examined whether hK2 protein and gene SNPs
predict prostate cancer at the time of repeat biopsy.
Methods: We prospectively offered a repeat biopsy to men with a negative prostate biopsy performed for a
PSA >4.0 ng/mL or abnormal Digital Rectal Exam (DRE) between 2001–2005. We genotyped and measured serum
hK2 levels in 941 men who underwent a repeat prostate biopsy. Logistic regression analyses were conducted to
determine the significance of KLK2 SNPs and hK2 levels for predicting cancer at repeat biopsy.
Results: Of the 941 patients, 180 (19.1%) were found to have cancer. The rs198977 SNP was positively associated
with cancer at repeat biopsy (OR variant T allele = 1.8, 95% CI: 1.04-3.13, p = 0.049). When combined, the odds ratio
for prostate cancer for patients with high hK2 levels and the variant T-allele of rs198977 was 3.77 (95% CI: 1.94-7.32,
p < 0.0001), compared to patients with low hK2 levels and the C-allele. The addition of hK2 levels and KLK2
rs198977 to the baseline predictive model did not significantly increase the area under the curve from a baseline
model of 0.67 to 0.69 (p = 0.6).
Conclusions: The KLK2 SNP rs198977 was positively associated with hK2 levels and predicts prostate cancer at the
time of repeat prostate biopsy. Further characterization of the KLK2 gene will be needed to determine its clinical
utility.
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Transrectal ultrasound guided biopsy of the prostate is
the gold standard to establish the diagnosis of prostate
cancer among prescreened men. Multiple needle cores
are obtained randomly within targeted areas of the pros-
tate gland, since tumour foci are too small to be visual-
ized. Despite the multiple samplings, areas of cancer
may be missed by the biopsy procedure and the false
negative rate has ranged from 10% to 30% (Rietbergen
et al. 1998; Durkan & Greene 1999). The practice of
conducting a repeat biopsy after an initial negative bi-
opsy is variable and not well established due to the lack
of definitive predictor variables that can identify patients* Correspondence: Robert.Nam@sunnybrook.ca
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reproduction in any medium, provided the origat high risk for having prostate cancer (Djavan et al.
2000; Roehl et al. 2002).
We and others have shown that a serine protease,
human kallikrein-2 (hK2), was positively associated
with prostate cancer (Klein et al. 2010; Nam et al.
2000; Herrala et al. 1997). We also showed that single
nucleotide polymorphisms (SNPs) of the KLK2 gene,
which encodes for the hK2 protein have been shown
to be associated with prostate cancer (Nam et al. 2003;
Nam et al. 2006; Nam et al. 2009).
To examine whether these factors could be used to de-
termine the presence of cancer among patients at the
time of repeat biopsy after an initial negative biopsy, we
conducted a prospective study among a cohort of men
who had previously undergone biopsy with no evidence
of prostate cancer. We offered a repeat biopsy among
these men and developed a nomogram to guide repeathis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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conducted decision curve analysis to determine whether
these factors related to hK2 provided additional predict-
ive value compared to conventional risk factors.
Materials and methods
Study subjects
The study subjects were drawn from a pre-screened
group of men at Sunnybrook Health Sciences Centre and
University Health Network (Toronto, Canada) who under-
went an initial prostate biopsy for either PSA >4.0 ng/mL
or abnormal DRE. After institutional research ethics board
(REB) approval, we offered all men over the age of 40
whom had an initial negative biopsy a repeat biopsy over
the period of 2001 to 2005. A total of 1200 consecutive
men with a negative biopsy over the study period were of-
fered a repeat biopsy within a span of 6 months to
12 months after the date of their initial biopsy. Of 1200
men, 941 (78%) agreed to undergo a repeat biopsy. All re-
peat biopsies followed an extended 12-core TRUS-guided
needle-biopsy technique (Babaian 2000).
Baseline demographic risk factors and blood samples
for serology and genotyping were collected prior to the
first biopsy. Serum PSA and hK2 levels were measured
using assays previously described (Nam et al. 2000).
Genotyping
We genotyped two polymorphisms (rs2664155/KL1 and
rs198977/KL2) of the KLK2 gene that we previously
showed to be positively associated with prostate cancer
risk (Nam et al. 2006). Genotyping was conducted using
mass-spectrometry-based genotyping analysis using matrix-
assisted laser desorption ionization – time of flight
(MassArray System, Sequenom Inc., San Diego, California,
USA) following the manufacturer’s instructions. Details
of the SNPs regarding location, allele type, location and
primers have been previously described in detail (Nam
et al. 2006).
Data analysis
Cases were defined as patients with adenocarcinoma of
the prostate on repeat biopsy and controls were men
with no evidence of cancer (including benign prostatic
hypertrophy, high-grade prostate intra-epithelial neopla-
sia and atypical small acinar proliferation). All baseline
risk factors between cases and controls were compared.
We ensured that KLK2 genotype frequencies were in
Hardy-Weinberg equilibrium when examined in the
control population. Serum hK2 levels and KLK2 geno-
type frequencies were compared between cases and con-
trols. Serum hK2 levels were analysed by quartiles,
which were based on the distribution of hK2 levels in
the control group. Conventional risk factors together
with hK2 levels and KLK2 genotype were examined usingmultivariable unconditional logistical regression modeling.
Both SNPs and serum hK2 levels, the variables of interest
in this study, were included in the multivariate model and
the inclusion of other variables into the final model was
based on significance in univariate analysis or if widely ac-
cepted as a risk factor (e.g. family history). We determined
the predictive value of our new model by comparing the
area under the receiver operating characteristics curve
(AUC) of our baseline risk model, which included age,
ethnic background, PSA, DRE, past histology, prostate
volume, and family history to the AUC after incorporating
KLK2 genotype and hK2 level. Bootstrap with 2000 repli-
cates was used to correct the over-fitting bias on the cal-
culation of the AUCs.
We also sought to incorporate hK2 levels and KLK2
genotype into a nomogram to estimate the probability of
prostate cancer at the time of repeat biopsy. This nomo-
gram was designed in order to predict all prostate cancers
as well as ≥Gleason 7 prostate cancer. We characterized
the clinical effects of this model using decision curve ana-
lysis (Vickers & Elkin 2006). This methodology estimates
the net benefit for predictive models by summing benefits
(true positives) and subtracting the harms (false positives),
whereby the latter is weighted using a factor related to the
relative harm of a missed cancer in comparison to an
unnecessary biopsy. The statistical significance is deter-
mined at a critical level of 0.05. Statistical analyses were
completed using SAS (Version 9.1, SAS Institute Inc.,
Cary, NC, USA) the open source software R-2.11.0
(R Development Core Team, 2010) with additional
package Design, and S-PLUS (Version 8, Insightful Cor-
poration, Seattle, WA, USA).
Results
A total of 941 men underwent repeat TRUS guided
needle-core biopsy, of which 180 (19.1%) were found to
have prostatic adenocarcinoma (cases). Of the patients
with cancer, 6 (3.3%), 121 (67.2%), 46 (25.6%) and 7
(3.9%) men had Gleason ≤5, 6, 7 and ≥8 adenocarcin-
oma, respectively. On univariate analysis, lower prostate
volume and non-benign initial biopsy histology (HGPIN
and ASAP) were associated with prostate cancer (Table 1).
Age, PSA, family history of prostate cancer, ethnicity,
urinary symptoms and DRE were not significantly associ-
ated with prostate cancer risk at the time of repeat biopsy
(Table 1). Serum hK2 levels were significantly higher
among cases (mean hK2 = 0.246 ng/mL) than controls
(mean hK2 = 0.228 ng/mL, p = 0.02), and the rs198977
KLK2 SNP was significantly associated with prostate
cancer (Table 1).
From multivariable analysis of the baseline risk factors,
age, TRUS volume, ethnic background and initial biopsy
histology were associated with prostate cancer on repeat
biopsy (Table 2). Among the two KLK2 SNP variants,
Table 1 Frequency distribution of established and putative risk factors for prostate cancer among cases and controls
Subgroup Cases (n = 180), (%) Controls (n = 761), (%) P (χ2)*
Age <50 4 (14.3) 24 (85.7) 0.19
50-60 41 (15.4) 225 (84.6)
60-70 87 (20.0) 348 (80.4)
>70 48 (22.6) 164 (77.4)
PSA (ng/mL) <10.0 120 (18.6) 527 (81.4) 0.65
10.0-20.0 46 (19.7) 188 (80.3)
>20.0 14 (23.3) 46 (76.7)
TRUS volume (cc) <47.0 77 (28.5) 193 (71.5) <0.0001
47.0-67.0 51 (21.0) 192 (79.0)
67.0-93.1 27 ( 12.7) 185 (87.3)
>93.1 25 (11.6) 191 (88.4)
Family history Negative 152 (18.5) 668 (81.5) 0.23
Positive 28 (23.1) 93 (76.9)
Presence of LUTS Negative 104 (21.4) 382 (78.6) 0.067
Positive 76 (16.7) 379 (83.3)
DRE Normal 130 (18.6) 569 (81.4) 0.61
Abnormal 48 (20.1) 191 (79.9)
Ethnic background Other 3 (9.1) 30 (90.9) 0.074
Asian 8 (11.9) 59 (88.1)
White 147 (19.4) 609 (80.6)
Black 22 (25.9) 63 (74.1)
Initial Biopsy Pathology Normal or BPH 93 (14.8) 537 (85.2) < 0.0001
HGPIN 62 (25.6) 180 (74.4)
ASAP 25 (36.2) 44 (63.8)
rs2664155 (KL1) GG 80 (18.4) 354 (81.6) 0.35
GA 74 (18.5) 326 (81.5)
AA 26 (24.3) 81 (75.7)
rs198977 (KL2) CC 70 (15.8) 374 (84.2) 0.018
CT 82 (20.9) 311 (79.1)
TT 28 (26.9) 76 (73.1)
Mean (Median) hK2 Level (ng/mL) 0. 246 (0.193) 0.228 (0.163) 0.02
Abbreviations: TRUS = Transrectal Ultrasound, DRE = Digital Rectal Exam, LUTS = Lower Urinary Tract Symptoms; *Chi-Square Test.
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at repeat biopsy (OR variant T allele = 1.81, 95% CI:
1.04-3.13, p = 0.049). Additionally, serum hK2 level was
associated with prostate cancer (OR = 2.03, 95% CI: 1.4-
2.99, p = 0.002, Table 2).
The area under the curve (AUC) for the baseline model,
which included age, ethnic background, PSA, DRE, past
histology, prostate volume, and family history was 0.67.
The addition of hK2 levels and the KLK2 SNPs to the
baseline predictive model increased the AUC to 0.69 (p =
0.586 for the difference by 2000 bootstrap resamples).
The relationships between rs198977 and hK2 levels
were examined using autosomal dominant and recessive
models (Table 3). The KLK2 rs198977 genotypes werepositively associated with hK2 levels (p = 0.02). When
combined, the odds ratio for prostate cancer for patients
with high hK2 levels and the variant T-allele of rs198977
was 3.77 (95% CI: 1.94-7.32, p < 0.0001), compared to
patients with low hK2 levels and the C-allele (Table 4).
We incorporated hK2 level and KLK2 SNPs to con-
struct a nomogram for calculating the probability of a
prostate cancer, and in particular, for ≥Gleason 7 pros-
tate cancer on repeat biopsy (Figure 1). Figure 2 shows
the decision curve for our full model, including both
KLK2 SNPs and hK2 level. The net benefit of the three
markers, however, was not superior to alternative strat-
egies, including performing biopsies based on conven-
tional risk factors.
Table 2 Multivariable analysis of KLK2 SNPs and hK2 levels in predicting the presence of prostate cancer at the time of
repeat biopsy
Subgroup Odds Ratio 95% CI P
Age 1.35 1.02 - 1.79 0.049
PSA (ng/mL) 1.41 1.02 - 1.96 0.092
DRE 1.20 0.80 - 1.80 0.372
Presence of LUTS 0.80 0.56 – 1.13 0.205
TRUS volume (cc) 0.33 0.24 - 0.45 < 0.0001
Family history 1.40 0.86 - 2.28 0.175
Ethnic background Other + Asian 1.00 0.006
White 2.30 1.15 - 4.62
Black 4.01 1.70 - 9.45
Initial Biopsy Pathology BPH or Normal 1.00
HGPIN 1.79 1.22 - 2.62 0.0002
ASAP 2.62 1.51 - 4.54
rs2664155 (KL1) GG vs. GA 1.47 0.84 - 2.57 0.218
GG vs. AA 1.14 0.78 - 1.69
rs198977 (KL2) TT vs. CT 1.23 0.72 – 2.09 0.049
TT vs. CC 1.81 1.04 – 3.13
hK2 Level (ng/mL) 2.03 1.4 – 2.99 0.002
Table 4 Adjusted Odds ratios for prostate cancer
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The purpose of this study was to examine predictors of
prostate cancer at repeat biopsy in a prospective fashion
with intent to re-biopsy all men with an initial negative
biopsy. Among pre-screened men undergoing a repeat
biopsy, we have found an association between the KLK2
SNP rs198977 as well as serum hK2 levels and prostate
cancer. Serum levels of hK2 were positively associated
with rs198977 variants, however, incorporation of these
markers to our model did not significantly improve its
predictive ability. While the latter highlights a potential
lack of clinical utility, hK2 and KLK2 SNPs may still have
a discriminatory role, but require further characterization.
Djavan et. al. published a large prospective study of
1050 men with PSA 4 to 10 ng/ml in whom systematic
sextant biopsies were performed in all those with nega-
tive initial biopsy (Djavan et al. 2000). Of the 820 men
with initial negative biopsies, 10% were found to have
prostate cancer on repeat biopsy, which was mostTable 3 Relationship between rs198977 genotype and
hK2 levels
KL2 Genotype hK2 Level
(ng/mL)*
KL2 Genotype hK2 Level
(ng/mL)*rs198977 rs198977
CC (n = 444) 0.214 ± 0.213 CC (n = 444) 0.214 ± 0.213
CT or TT (n = 497) CT (n = 393) 0.240 ± 0.241
0.247 ± 0.243 TT (n = 104) 0.271 ± 0.251
P (between genotypes) 0.03 0.02
Abbreviations: C, Wild-Type Allele; T, Variant Allele. *t-test.strongly predicted by percent free PSA and transition
zone PSA. The low detection rates of prostate cancer on
repeat biopsy was likely due to the exclusion of men
with PSA >10. No other novel factors were examined.
More contemporary studies have consisted of case series
with a focus on PSA and rate of change. While there
have been nomograms derived from these studies, they
offer conflicting evidence on the role of PSA and its cal-
culated kinetics (e.g. doubling time) in predicting pros-
tate cancer in the repeat biopsy setting (Moussa et al.
2010; Benecchi et al. 2008).
This current study adds to the observation that PSA is
a poor marker for guiding which patients require a re-
peat biopsy. In the setting of repeat prostate biopsy, per-
cent free PSA and PSA density may be useful (Djavan
et al. 2000), however, the only established predictors of
prostate cancer are the presence of high grade prostaticdetection for each combination of rs198977 Genotype
and circulating hK2 levels
KL2 Genotype
rs198977
hK2 Level CC CT or TT
OR (95% CI) P OR (95% CI) P
< 0.101 1.00 - 0.86 ( 0.40 - 1.83) 0.22
0.101-0.163 1.51 (0.7 - 3. 2) 0.81 1.49 (0.75 - 2.97) 0.74
0.163-0.289 1.42 ( 0.68-2.98) 0.61 3.77 (1.94 - 7.32) < 0.0001
>0.289 1.59 (0.71-3.55) 0.97 2.65 (1.29 - 5.44) 0.026
Figure 1 Nomogram for predicting prostate cancer (PCa) at the time of repeat biopsy. The nomogram is used by localizing a patient’s
position for each variable along its horizontal axis to determine a point value according to the points scale (top axis). The total points corresponds a
probability value of having prostate cancer or≥Gleason 7 (high grade) prostate cancer. Note: PSA (ng/ml), LUTS = Lower Urinary Tract Symptoms,
rs2664155/KL1 (AA =Wild Type; AG= heterozygote; GG = variant), rs198977/KL2 (CC =Wild Type; CT = heterozygote; TT = variant), hk = hK2 level (pg/mL).
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acinar-cell proliferation (ASAP) (Epstein & Potter 2001).
Recent studies have shown that ASAP and HGPIN can
increase risk of prostate cancer by 42% and 16% respect-
ively in patients undergoing repeat extended core biopsy
(Campos-Fernandes et al. 2009). In our analysis of risk
factors, we have show that the presence of HGPIN re-
mains a strong predictor of prostate cancer on repeatbiopsy, despite the fact its role has been questioned in
recent literature (Gallo et al. 2008).
The biology of prostate cancer, particularly, the shared
androgen dependence of PSA and hK2, taken together
with our previous work adds to the mounting evidence
that KLK2 is a prostate cancer susceptibility gene. While
it is established that hK2 activates the precursor of PSA,
the role of this serine protease in normal and malignant
Figure 2 Decision curve for outcome of any prostate cancer using the three markers studied (rs198977/KL2, rs2664155/KL1 and hK2
level). The 3 marker strategy (black dashed line) is compared to the baseline model (red dashed line) and to a strategy of biopsying all men
(solid grey line) or biopsying no men (solid black line).
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SNPs studied may modulate enzymatic activity and their
relationship to serum hK2 levels. In our previous work,
the group of patients having the highest quartile of hK2
level and ‘T’ variant of rs198977 (KL2) had the highest
risk (OR 13.9, p = 0.0001) (Nam et al. 2003). The variant
(TT) genotype of KL2 positively correlated with hK2
levels in this study, whereas the opposite effect had been
demonstrated previously (Nam et al. 2006).
Our previous work has established the utility of hK2
levels and KLK2 SNPs in the screening setting (Nam
et al. 2000; Nam et al. 2003; Nam et al. 2006). More re-
cently, others have integrated hK2 with intact, total, and
free PSA to construct a “kallikrien-panel” that has been
shown to improve the prediction of prostate cancer in
previously unscreened men with an elevated PSA
(>3 ng/mL) derived from the Rotterdam cohort of the
ERSPC (European Randomized Study of Screening for
Prostate Cancer) (Vickers et al. 2008). Gupta et al. ap-
plied this panel to men with negative initial biopsies,however, only 40% of men underwent repeat biopsy, due
to refusal or a PSA of less than 3.0 ng/mL which may
explain the low cancer detection rate of 12% (Gupta
et al. 2010). Nevertheless, the addition of the panel con-
taining hK2 to a baseline model appeared to improve
the AUC. However, the authors did not control for initial
biopsy histology such as ASAP or HGPIN.
The strength of this study lies in a large prospective
cohort that was rigorously offered repeat biopsy. We
have, for the first time, incorporated hK2 levels with a
novel SNP to enhance the prediction of prostate cancer
in this setting. Nonetheless, while our nomogram may
have clinical utility, the added improvement to this in-
strument by the addition of hK2 and KL2 SNP was min-
imal and not statistically significant. In our analysis, the
predictive ability of our model only improved minimally
from 0.67 to 0.69 and was not significant. Moreover, de-
cision curve analysis did show improved net benefit over
the clinical model across most threshold properties, al-
though this is a minimal benefit. Future direction for
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improve prediction, and validation of this nomogram in
other cohorts.
Conclusions
The KLK2 SNP rs198977 was found to be positively as-
sociated with hK2 levels and shown to predict prostate
cancer at the time of repeat prostate biopsy. Incorpor-
ation of this marker into our model did not significantly
improve its predictive ability. Further work is required
to characterize the KLK2 gene to potentially improve its
clinical utility.
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